Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 9637528
    Abstract: The invention provides directed evolution methods for improving the folding, solubility and stability (including thermostability) characteristics of polypeptides. In one aspect, the invention provides a method for generating folding and stability-enhanced variants of proteins, including but not limited to fluorescent proteins, chromophoric proteins and enzymes. In another aspect, the invention provides methods for generating thermostable variants of a target protein or polypeptide via an internal destabilization baiting strategy. Internally destabilization a protein of interest is achieved by inserting a heterologous, folding-destabilizing sequence (folding interference domain) within DNA encoding the protein of interest, evolving the protein sequences adjacent to the heterologous insertion to overcome the destabilization (using any number of mutagenesis methods), thereby creating a library of variants. The variants in the library are expressed, and those with enhanced folding characteristics selected.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: May 2, 2017
    Assignee: Los Alamos National Security, LLC
    Inventors: Andrew M. Bradbury, Csaba Kiss, Geoffrey S. Waldo
  • Patent number: 9603944
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 28, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Li Tang, Darrell J. Irvine
  • Patent number: 9605083
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 28, 2017
    Assignee: Emory University
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Patent number: 9598512
    Abstract: Disclosed are an ultra-high molecular weight polyethylene resin for fiber and a preparation method thereof. The initial crystallinity of the resin is 60.5 to 90%, the volume average particle size is between 100 and 350 ?m, the particle-size distribution is 1.0-2.1, the molecular weight is 2-7 million, the tensile breaking stress is 30 to 60 MPa, the bulk density of the resin is 0.10 to 0.50 g/cm3, the infiltration time in the solvent decalin is 0.5 to 11 min, the decalin absorption amount of the resin is 2 to 50 g of decalin per 100 g of ultra-high molecular weight polyethylene resin, and the white oil absorption amount is 5 to 60 g of decalin per 100 g of ultra-high molecular weight polyethylene resin. The ethylene homopolymerization is performed using a slurry polymerization process in the presence of a main catalyst and a co-catalyst.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: March 21, 2017
    Assignee: CHINA PETROLEUM & CHEMICAL CORPORATION
    Inventors: Jianyong Zhou, Xiaoqing Li, Liuzhong Li, Xiaolong Bi, Wenyi Li, Yongling Yu
  • Patent number: 9592286
    Abstract: The present disclosure provides vaccine compositions comprising a PRRSV vaccine and a second porcine vaccine, which are substantially free from immuno-inhibition against each other. The second porcine virus vaccine can be CSFV and/or PRV. The preparation methods for the vaccines and the formulations are also provided. The vaccine compositions provided herein confer protective immunity to pigs against porcine reproductive and respiratory syndrome, classical swine fever, and/or pseudorabies.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: March 14, 2017
    Assignee: Sinovet (Beijing) Biotechnology Co., Ltd.
    Inventors: Hua Wu, Yanliang He, Mingqi Xia
  • Patent number: 9593018
    Abstract: Provided are a carbon nanotube composite containing a carbon nanotube coated with a protein having a catechol group and a metal ion bound to the catechol group and a method for manufacturing the same. According to the present disclosure, a carbon nanotube composite which exhibits controllable dispersibility and degree of crosslinkage while retaining the intrinsic physical properties of the carbon nanotube may be prepared. Since the phase change and tendency of aggregation of the carbon nanotube composite can be controlled quickly and repeatedly depending on the change in external environment, the carbon nanotube composite may be useful in various industrial fields including medicine, environment, etc. as a self-healing material.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 14, 2017
    Assignee: Korea Institute of Science and Technology
    Inventors: Yong Chae Jung, Sang Hyun Lee, Min Park
  • Patent number: 9587023
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Patent number: 9578890
    Abstract: Methods are described for treating a whey protein mixture to increase a relative concentration of ?-lactalbumin protein in the mixture. The methods may include the step of adjusting a temperature of the whey protein mixture to about 10° C. or less, and adjusting the pH of the mixture to greater than 7. The may further include adding a protease enzyme to the whey protein mixture that selectively hydrolyzes ?-lactoglobulin protein in the mixture. The activity of the protease enzyme in the hydrolyzed whey protein mixture may be terminated before a substantial portion of the ?-lactalbumin protein has been hydrolyzed by the enzyme. In some instances, the whey protein mixture may also include glycomacropeptides that are selectively hydrolyzed with the ?-lactoglobulin protein. The ?-lactoglobulin and glycomacropeptide hydrolysates may be separated to produce an enhanced ?-lactalbumin protein composition for infant formula, among other products.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: February 28, 2017
    Assignee: Leprino Foods Company
    Inventors: Jiancai Li, Richard K. Merrill
  • Patent number: 9580513
    Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: February 28, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Qi Zeng
  • Patent number: 9572838
    Abstract: A method for production of anti-tumor TRAIL includes inserting a TRAIL molecule, encoded by a viral vector irreversibly derived from a cell line, into a carrier cell, thereby obtaining a stably TRAIL-producing carrier cell, and wherein the TRAIL molecule includes a soluble molecule.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 21, 2017
    Inventors: Massimo Dominici, Rita Bussolari, Giulia Grisendi, Pierfranco Conte
  • Patent number: 9575075
    Abstract: The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 21, 2017
    Assignees: INSERM (Institut National de la Sante et Recherche Medicale), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
  • Patent number: 9567374
    Abstract: The present invention proposes a method for generating cyan fluorescent proteins which have reduced pH sensitivity, in particular acid-pH sensitivity.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 14, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERWSITE PARIS-SUD 11
    Inventors: Hélène Pasquier, Fabienne Merola, Marie Erard, Agathe Espagne, Asma Fredj
  • Patent number: 9562091
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Patent number: 9555087
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: January 31, 2017
    Assignee: COMPUGEN LTD
    Inventors: Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Yeshah Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levi, Sergey Nemzer, Tania Pergam, Yaron Kinar, Shirley Sameach- Greenwald, Zurit Levine, Shira Walach
  • Patent number: 9533027
    Abstract: Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(?-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(?-methyl ?-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 3, 2017
    Assignee: Vindico NanoBioTechnology, LLC
    Inventors: P. Peter Ghoroghchian, Eric Ostertag
  • Patent number: 9534028
    Abstract: The present invention relates to a method for the preparation of a concentrate of serum proteins with reduced lactose content from a sample of lactoserum, wherein said concentrate is characterized in that it comprises a concentration of 0.5 grams of lactose per kilogram of protein, the concentrate obtainable from said process and food products containing said concentrate.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: January 3, 2017
    Assignee: LB LYOPHARM S.R.L.
    Inventor: Christian Rebière
  • Patent number: 9533035
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: January 3, 2017
    Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.
    Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia
  • Patent number: 9522940
    Abstract: The present invention relates to novel, specific-binding therapeutic and/or diagnostic lipocalin muteins directed against Glypican-3 (GPC-3). The invention also relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the invention also is directed to pharmaceutical compositions comprising such muteins and practical uses of these lipocalin muteins. In addition, the present invention provides methods of using muteins of human lipocalin 2 (Lcn2 or NGAL) for target-specific delivery of therapeutic moieties or detectable labels to cells expressing GPC-3, and related therapeutic and diagnostic utilization.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 20, 2016
    Assignee: Pieris Pharmaceuticals GmbH
    Inventor: Klaus Kirchfield
  • Patent number: 9518254
    Abstract: The invention is directed to compositions to screen for small molecule drugs that inhibit proteases, such as viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., HIV proteases. In alternative embodiments, the invention provides cell-based assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelop protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products.
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: December 13, 2016
    Assignee: San Diego State University Research Foundation
    Inventor: Roland Wolkowicz
  • Patent number: 9518111
    Abstract: The present invention relates to pharmaceutical compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: December 13, 2016
    Assignee: Immunex Corporation
    Inventors: Wayne Richard Gombotz, Richard L. Remmele, Jr.
  • Patent number: 9511131
    Abstract: Chimeric fHBPs that can elicit antibodies that are bactericidal for different fHBP variant strains of N. meningitidis, and methods of use, are provided.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: December 6, 2016
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Peter Beernink, Jo Anne Welsch
  • Patent number: 9512210
    Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: December 6, 2016
    Assignees: GLIKNIK INC., UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Scott E. Strome, Dan H. Schulze, David S. Block, Henrik Olsen
  • Patent number: 9506167
    Abstract: Systems, methods, libraries, kits, and computer software tools are provided for designing and producing engineered cells. Such engineered cells can be used for cell state quantification, such as genome, transcriptome and/or proteome quantification. In one aspect, an engineered cell having a plurality of artificially designed oligonucleotides introduced into the genome of the cell is provided. The oligonucleotides are each located in proximity of a gene of interest encoding a protein of interest, and are different from one another. The oligonucleotides can each encode a unique peptide tag for each protein of interest, wherein each peptide tag has a unique quantitatively measurable value such as mass-to-charge ratio which can be quantified by a mass spectrometer. The engineered cell is capable of expressing a plurality of proteins of interest each fused to its corresponding unique peptide tag, wherein each peptide tag is capable of being released therefrom.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: November 29, 2016
    Assignee: GINKGO BIOWORKS, INC.
    Inventors: Reshma Shetty, Thomas F. Knight, Jr., Randall D. Rettberg
  • Patent number: 9506049
    Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: November 29, 2016
    Assignees: Novozymes A/S, Novozymes, Inc.
    Inventors: Lan Tang, Ye Liu, Junxin Duan, Yu Zhang, Christian Joergensen, Randall Kramer
  • Patent number: 9505843
    Abstract: Provided is an anti-Her3 antibody or antigen-binding fragment thereof, an anti-c-Met/anti-Her3 bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: November 29, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Min-Kyung Kim, Kwang Ho Cheong, Mi Young Cho, Powei Lin
  • Patent number: 9499813
    Abstract: Embodiments of various aspects described herein are directed to amplification of biological entities, for example, for phage display. In one aspect, members of a library of biological entities are encapsulated in separate compartments (e.g., in separate microfluidic droplets) and amplified. For example, by putting members of a phage display library into microfluidic droplets such that no droplet contains more than one member of the library, the library can be amplified without any substantial changes in population distributions, or other artifacts created due to differences in growth rates or amplification between different members of the library. In some cases, the volume of the compartments can be used to control the copy number of a biological entity during amplification. This can be advantageous, for example, in preserving diversity within a library by preventing rapidly amplifying biological entities from outcompeting slowly amplifying biological entities.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: November 22, 2016
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Ratmir Derda, Sindy K. Y. Tang, George M. Whitesides
  • Patent number: 9499810
    Abstract: Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: November 22, 2016
    Assignee: aTyr Pharma, Inc.
    Inventors: Rajesh Belani, Jeffry Dean Watkins, Wei Zhang, Alain Phillippe Vasserot
  • Patent number: 9493545
    Abstract: Based on the three-dimensional structure of albumin, the inventors have designed variant polypeptides (muteins) which have one or more cysteine residues with a free thiol group (hereinafter referred to as “thio-albumin”). The variant polypeptide may be conjugated through the sulphur atom of the cysteine residue to a conjugation partner such as a bioactive compound.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: November 15, 2016
    Assignee: Albumedix A/S
    Inventors: Christopher John Arthur Finnis, Joanna Mary Hay, Esben Peter Friis, Darrell Sleep
  • Patent number: 9492501
    Abstract: The present invention describes the use of a composition including or constituted by at least one element chosen from: a specific protein including or consisting of the amino acid sequence SEQ ID NO: 5, and a protein homologous to the specific protein, for the preparation of a medicament intended for the prevention or treatment of pathologies associated with a viral infection or an inflammation.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: November 15, 2016
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE STRASBOURG, UNIVERSITE DE LA MEDITERRANEE
    Inventors: Eric Chabriere, Mikael Elias, Olivier Rohr, Christian Schwartz
  • Patent number: 9486498
    Abstract: A method for treating a CD40-mediated disease in a subject includes administering to cells expressing CD40 of the subject a therapeutically effective amount of an agent that inhibits binding of TNF receptor associated factor 2 (TRAF2) to a cytoplasmic portion of CD40.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: November 8, 2016
    Assignee: Case Western Reserve University
    Inventors: Carlos Subauste, Cecilia Subauste
  • Patent number: 9486006
    Abstract: Moisture is retained in cooked or thawed food by adding to the food an aqueous suspension of animal muscle protein obtained from animal muscle tissue. The aqueous suspension is obtained by mixing comminuted animal muscle tissue with a food grade base to form an aqueous basic solution of animal muscle protein. The basic solution is mixed with a food grade acid to precipitate the protein in an aqueous composition. The precipitated protein then is comminuted to form an aqueous suspension of comminuted animal muscle protein.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: November 8, 2016
    Assignee: Proteus Industries, Inc.
    Inventors: Stephen D Kelleher, William R. Fielding, Wayne S. Saunders, Peter G. Williamson
  • Patent number: 9481717
    Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present invention provides antiviral and antimicrobial lectin compounds and methods of their use.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: November 1, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David Markovitz, Michael Swanson, Irwin Goldstein, Harry Winter
  • Patent number: 9475855
    Abstract: This invention provides a fusion protein comprising a signal peptide, EGF repeats 1-X of the extracellular domain of human Notch3 receptor protein wherein X is any integer from 12 to 34, and an Fc portion of an antibody bound thereto. This invention also provides a method for treating a subject having a tumor, a method for inhibiting angiogenesis in a subject, a method for treating a subject having ovarian cancer, and a method for treating a subject having a metabolic disorder, comprising administering to the subject an amount of the above fusion protein effective to treat the subject. This invention further provides uses of the above fusion protein for the preparation of a pharmaceutical composition for the treatment of a subject having a tumor, for inhibiting angiogenesis in a subject, for treating a subject having ovarian cancer, and for treating a subject having a metabolic disorder.
    Type: Grant
    Filed: August 21, 2009
    Date of Patent: October 25, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jan Kitajewski, Carrie Shawber
  • Patent number: 9464311
    Abstract: The present invention provides a screen which exploits mechanism-based activity probes that specifically and covalently modify the active site cysteine thiol residue of E3 Ub ligases including, but not limited to the HECT and RBR family. The activity probes are used to screen for activators and inhibitors of E3 Ub ligases, and to interrogate the functional state of E3 Ub ligases in human disease.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: October 11, 2016
    Assignee: E3X Bio, Inc.
    Inventors: Brigit Riley, Jennifer Johnston, David Morgans
  • Patent number: 9459259
    Abstract: In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: October 4, 2016
    Assignee: Senomyx, Inc.
    Inventors: Guy Servant, Hong Chang, Cyril Redcrow, Sumita Ray, Imran Clark, Bryan Moyer
  • Patent number: 9458374
    Abstract: A produced water bacterial pretreatment method which includes a) optionally adjusting a pH and a temperature of a produced water containing bacteria; b) adding a cysteine protease to said produced water; c) allowing said cysteine protease to inactivate said bacteria, thus producing pretreated produced water; and d) introducing said pretreated produced water into a wellbore penetrating a subterranean formation is provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 4, 2016
    Assignee: SCHLUMBERGER TECHNOLOGY CORPORATION
    Inventor: Daniel Denton Sorrells
  • Patent number: 9453065
    Abstract: The disclosure relates to the field of GPCR structure biology and signaling. In particular, it relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, it provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains hereof can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, also encompassed are the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: September 27, 2016
    Assignees: VIB VZW, Vrije Universiteit Brussel, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jan Steyaert, Els Pardon, Soren Rasmussen, Juan Fung, Brian Kobilka, Toon Laeremans
  • Patent number: 9445990
    Abstract: A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37° C., and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5 cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: September 20, 2016
    Assignee: Medtronic, Inc.
    Inventors: Deanna S. Lane, Charlene X. Yuan, Jianwei Li, Lanchi T. Le
  • Patent number: 9441013
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: September 13, 2016
    Assignees: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC, ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 9434774
    Abstract: Aggregation is a major cause of the misbehavior of proteins. A system for modifying a protein to create a more stable variant is provided. The method involves identifying non-conserved hydrophobic amino acid residues on the surface of a protein, suitable for mutating to more hydrophilic residues (e.g., charged amino acids). Any number of residues on the surface may be changed to create a variant that is more soluble, resistant to aggregation, has a greater ability to re-fold, and/or is more stable under a variety of conditions. The invention also provides GFP, streptavidin, and GST variants with an increased theoretical net charge created by the inventive technology. Kits are also provided for carrying out such modifications on any protein of interest.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: September 6, 2016
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Kevin John Phillips, Michael S. Lawrence
  • Patent number: 9434765
    Abstract: The potential use of these “SUMO receptors” to isolate SUMOylated targets has been considered using the SIM sequences of the SUMO-dependent ubiquitin-protein ligase RNF4. RFN4 contains 4 SIM sequences known to interact with SUMOylated proteins. The capacity of the SIM2 and SIM3 of RNF4 to purify SUMOylated proteins was increased when in the present invention it was disposed in tandem up to 4 SIM sequences. In a preferred embodiment to increase flexibility and functionality of this SUMO-trap, we have changed the natural linkers resulting in a broader capture of SUMOylated proteins. This Tandem SUMO Interacting Motifs (TSIMs) or SUMO-Binding Entities (SUBEs) system disclosed in the present invention is useful to capture polySUMOylated proteins from cell extracts. Therefore, in another embodiment of the present invention, TSIMs or SUBEs can be used for the identification SUMO substrates and the study of SUMO-regulated processes.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: September 6, 2016
    Assignee: ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE
    Inventor: Manuel Salvador Rodríguez Medina
  • Patent number: 9428574
    Abstract: This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections.
    Type: Grant
    Filed: July 1, 2012
    Date of Patent: August 30, 2016
    Assignee: COMPUGEN LTD.
    Inventors: Amir Toporik, Avi Yeshah Rosenberg, Galit Rotman, Iris Hecht, Zurit Levine
  • Patent number: 9428769
    Abstract: A liposome comprising a region of a lipid bilayer membrane with different membrane thicknesses, wherein each lipid bilayer membrane region is composed of a different lipid, and a thick membrane side in the region of the lipid bilayer membrane is formed of lipid having a phase transition temperature higher than that of the lipid forming a thin membrane side in the region of the lipid bilayer membrane. A proteoliposome, wherein the above-described liposome includes membrane proteins. A biochip, wherein the above-described liposome or the above-described proteoliposome is spread on a substrate. The above-described biochip, wherein the substrate includes at least one kind selected from the group consisting of mica, SiO2, SiN, Au and Pt.
    Type: Grant
    Filed: November 26, 2008
    Date of Patent: August 30, 2016
    Assignees: Nippon Telegraph and Telephone Corporation, Isis Innovation Ltd.
    Inventors: Chandra Sekar Ramanujan, Nahoko Kasai, Keiichi Torimitsu, John F. Ryan
  • Patent number: 9410136
    Abstract: The present invention relates to methods for degrading or converting a cellulosic material and for producing a substance from a cellulosic material.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: August 9, 2016
    Assignee: Novozymes, Inc.
    Inventors: Kirk Schnorr, Randall Kramer
  • Patent number: 9403883
    Abstract: An object of the present invention is to create a novel engineered Protein A ligand having better antibody dissociation properties in the presence of an acid than conventional engineered Protein A ligands and a further object of the present invention is to create a novel engineered Protein A ligand having higher alkali resistance. The present invention is to provide a protein having an affinity for an immunoglobulin, including an amino acid sequence derived from any of E, D, A, B and C domains of Protein A, wherein at least one Gly residue in the amino acid sequence is replaced with an amino acid other than Ala, and the protein has a lower affinity for an Fab region of an immunoglobulin than a protein including an amino acid sequence in which the Gly residue is replaced with Ala. Also, the present invention is to provide the protein having an affinity for an immunoglobulin, which has improved chemical stability in an alkaline condition compared to the corresponding domain.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: August 2, 2016
    Assignee: KANEKA CORPORATION
    Inventors: Shinichi Yoshida, Dai Murata, Masayuki Takano, Junya Akagi, Keita Iguchi, Yoshiyuki Nakano
  • Patent number: 9404928
    Abstract: The invention provides methods and systems of determining biopolymer profiles and correlations between structural units (residues) of a biopolymer based on sampling of the conformational space available to the molecule. The correlations between these structural units can further be used to find networks within a biopolymer such as the coupled residue networks in a protein. The invention also provides for designing and engineering biopolymers including polypeptides, nucleic acids and carbohydrates using the information derived from the conformation clustering and subsequent methods described herein.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: August 2, 2016
    Assignee: ZYMEWORKS INC.
    Inventors: Paula I. Lario, Johannes Mullegger, Anne-Marie Baribeau, Surjit B. Dixit, Tomas Rodinger, Powell Patrick Cheng Tan
  • Patent number: 9399056
    Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: July 26, 2016
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Jian Yan, Bernadette Ferraro, Niranjan Y. Sardesai, Mathura P. Ramanathan
  • Patent number: 9400249
    Abstract: Systems and methods for detecting protein-protein interactions and/or detecting a targeted cell using a split supercharged protein reporter system are described.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: July 26, 2016
    Assignee: Colorado State University Research Foundation
    Inventors: Brian R. McNaughton, Alex M. Chapman, Brett Blakeley
  • Patent number: 9393294
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: July 19, 2016
    Assignees: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley
  • Patent number: 9388230
    Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: July 12, 2016
    Assignees: KAHR MEDICAL(2005) LTD, HADASIT MEDICAL RESEARCH SERVICE AND DEVELOPMENT CO. LTD.
    Inventor: Michal Dranitzki Elhalel